300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Biotechnology
Legal
Automotive
eSports
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Manufacturing
FinTech
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Togo
Nigeria
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Iran
Isle of Man
Madagascar
Lesotho
Nepal
Russian Federation
Pakistan
Turkey
Liberia
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Kuwait
Czech Republic
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Guatemala
Switzerland
Sri Lanka
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Bangladesh
Angola
Europe
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
San Marino
Slovenia
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Sino Biopharmaceutical, VC Fund

Sino Biopharmaceutical

VC Fund

Wan Chai, Hong Kong

Sino Biopharmaceutical is a VC fund in Wan Chai focused on Biotechnology and Health Care. Sino Biopharmaceutical engages in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumours, liver diseases, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopedicdiseases.

Total investments:
17
Last investment:
Lead investor:
47%

Last updated:

Industries Sino Biopharmaceutical invests in

BiotechnologyHealth CareMedicalBiopharmaManufacturing

Stages Sino Biopharmaceutical invests in

Series BSeries DSeries ASeries CVenture - Series Unknown

Countries Sino Biopharmaceutical invests in

ChinaUnited StatesIsraelTaiwanSingapore

Round sizes

Series A $20M–$290MSeries B $91M–$110MSeries D $27M–$400M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$20M–$290M
Series B
$91M–$110M
Series D
$27M–$400M

Investment Focus

Industry

  • Biotechnology 10 (59%)
  • Health Care 7 (41%)
  • Medical 6 (35%)
  • Biopharma 5 (29%)
  • Manufacturing 4 (24%)
See all 15 industries →

Stage

  • Series B 3 (18%)
  • Series D 3 (18%)
  • Series A 2 (12%)
  • Series C 2 (12%)
  • Venture - Series Unknown 2 (12%)
See all 10 stages →

Country

  • China 11 (65%)
  • United States 3 (18%)
  • Israel 1 (6%)
  • Taiwan 1 (6%)
  • Singapore 1 (6%)

Team

NameTitleInvestmentsLinksEmail
Hsin Tse
Hsin Tse Executive Director and VP
Executive Director and VP Total investments: 2 Find email
Ping Tse Founder & Sr. Vice Chairman
Founder & Sr. Vice Chairman Total investments: 0 Find email
Yi Li
Yi Li President & CEO
President & CEO Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
Anew Labs develops generative AI platforms and foundation models to accelerate drug discovery, including protein structure prediction, antibody design, and cellular dynamics forecasting. The company integrates its computational engines with experimental feedback to advance pipelines targeting diseases like inflammatory conditions. Its business model centers on side-by-side collaboration between machine learning researchers and biotechnology experts to create synthesizable molecular pathways and clinical candidates. $290M / Series A / Sep 16, 2026
Hongxin Biology Hongxin Biology
Hongxin Bio is an mRNA drug developer, focusing on nucleic acid drug delivery and RNA drug development. Series B / Aug 13, 2026
TranscEngram is an AI research and technology company focused on advancing artificial intelligence. Angel / Jul 05, 2026
AI² Robotics is a robotics and embodied artificial intelligence company that develops, manufactures, and deploys general-purpose intelligent robots for industrial and commercial applications. The company focuses on extending artificial general intelligence (AGI) into the physical world through embodied AI, combining proprietary foundation models, robotics hardware, and large-scale deployment capabilities. Its mission is to make general-purpose robots as widely accessible as smartphones and smart vehicles, enabling them to perform repetitive, labor-intensive, and hazardous tasks across diverse industries. Its flagship AlphaBot series comprises wheeled, dual-arm humanoid robots powered by its proprietary AlphaBrain embodied foundation model. AlphaBrain integrates real-time perception, spatial reasoning, whole-body motion control, and long-horizon task planning, enabling robots to understand three-dimensional environments, manipulate objects, and autonomously execute complex tasks. AI² Robotics also develops supporting technologies, including teleoperation systems, simulation environments, and robot learning platforms that accelerate model training and deployment. $735.9M / Series C / Jun 29, 2026
Sanegene Bio
Sanegene Bio is currently operating in stealth mode. $110M / Series B / Dec 08, 2025
Phrontline Biopharma specializes in the development of ADC to address unmet medical needs in the field of oncology. $60M / Seed / Nov 21, 2025
PaiLin Biotech
PaiLin Biotech is a specialized blood product provider focused on the production, collection, storage, and sales of high-quality single-donor plasma. $534.4M / Post-IPO Equity / Jun 11, 2025
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs. $42.2M / Series C / Oct 18, 2024
HanchorBio is a Biotechnology Research firm that is working to revolutionize the treatment of people with cancer. $20M / Series A / Aug 25, 2022
Generon (Shanghai) Corporation Ltd. is an integrated biotech company developing therapeutic biologics for patients world-wide. Their research & development center is located in Zhang Jiang High-Tech Park, Shanghai, China. their cGMP drug manufacturing facility is located in Economic-Technological Development Area, Beijing, China. Theirmission is “Innovating for Life” to develop innovative therapeutic biologics for global patients with unmet medical needs. They employ their proprietary, cutting-edge technology platforms to discover, develop and manufacture biologic therapeutics. They are focused on “best-in-class” and “first-in-class” recombinant therapeutic proteins to treat cancer, autoimmune and inflammatory diseases. They follow international quality standards for their product development and adhere to regulatory requirements of the CFDA, FDA and EMA. “Innovation and quality” are the soul of Generon in the generation of scientific data and in the processes of drug discovery, development and manufacturing. $70M / Venture - Series Unknown / Jun 02, 2022
See all 17 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Biotechnology
Legal
Automotive
eSports
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Manufacturing
FinTech
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Togo
Nigeria
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Iran
Isle of Man
Madagascar
Lesotho
Nepal
Russian Federation
Pakistan
Turkey
Liberia
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Kuwait
Czech Republic
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Guatemala
Switzerland
Sri Lanka
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Bangladesh
Angola
Europe
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
San Marino
Slovenia
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Sino Biopharmaceutical invest in?

Sino Biopharmaceutical invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series D stage. Most of the 17 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Sino Biopharmaceutical invest in?

Sino Biopharmaceutical typically joins rounds of $20M–$290M at Series A, $91M–$110M at Series B and $27M–$400M at Series D. These are whole funding-round sizes, not Sino Biopharmaceutical's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Sino Biopharmaceutical took part in.

How do I contact Sino Biopharmaceutical?

Public channels for Sino Biopharmaceutical include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Sino Biopharmaceutical?

The team at Sino Biopharmaceutical includes Hsin Tse (Executive Director and VP), Ping Tse (Founder & Sr. Vice Chairman) and Yi Li (President & CEO). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Sino Biopharmaceutical Sino Biopharmaceutical Find emails